Skip to content
10-K

Annual Report

VERTEX PHARMACEUTICALS INC / MA VRTX

0000875320-25-000053

← back to feed
Filed
Feb 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 7, 2025 256.79M sh
Current Liabilities FY 2024 · Dec 31, 2023 $3.55B
Total Liabilities FY 2024 · Dec 31, 2023 $5.15B
Current Assets FY 2024 · Dec 31, 2023 $14.14B
Total Assets FY 2024 · Dec 31, 2023 $22.73B
Shares Diluted FY 2024 · Dec 31, 2022 259.1M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $0
Capex FY 2024 · Dec 31, 2022 $204.7M
Operating Cash Flow FY 2024 · Dec 31, 2022 $4.13B
Eps Diluted FY 2024 · Dec 31, 2022 $12.82
Eps Basic FY 2024 · Dec 31, 2022 $12.97
Sga Expense FY 2024 · Dec 31, 2022 $944.7M
Net Income FY 2024 · Dec 31, 2022 $3.32B
Operating Income FY 2024 · Dec 31, 2022 $4.31B
Cost Of Revenue FY 2024 · Dec 31, 2022 $1.08B
Revenue FY 2024 · Dec 31, 2022 $8.93B
Cash And Equivalents FY 2024 · Dec 31, 2021 $6.8B
Stockholders Equity FY 2024 · Dec 31, 2021 $10.1B